These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 29406821)
1. Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. Tian WH; Wang Y; Yang R; Hu HB J Altern Complement Med; 2018 May; 24(5):481-485. PubMed ID: 29406821 [TBL] [Abstract][Full Text] [Related]
2. Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Ugur-Altun B; Altun A; Arikan E; Guldiken S; Tugrul A Endocr Res; 2003 Nov; 29(4):389-98. PubMed ID: 14682468 [TBL] [Abstract][Full Text] [Related]
3. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study. Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines. Yang H; Cong Y; Wu T; Tang H; Ma M; Zeng J; Zhang W; Lian Z; Yang X Pharm Biol; 2017 Dec; 55(1):258-263. PubMed ID: 27927064 [TBL] [Abstract][Full Text] [Related]
5. Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy. Molnár I; Szentmiklósi JA; Gesztelyi R; Somogyiné-Vári É Clin Exp Med; 2019 May; 19(2):245-254. PubMed ID: 30610492 [TBL] [Abstract][Full Text] [Related]
6. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. Leo M; Bartalena L; Rotondo Dottore G; Piantanida E; Premoli P; Ionni I; Di Cera M; Masiello E; Sassi L; Tanda ML; Latrofa F; Vitti P; Marcocci C; Marinò M J Endocrinol Invest; 2017 Mar; 40(3):281-287. PubMed ID: 27734319 [TBL] [Abstract][Full Text] [Related]
7. [Clinical aspects, diagnosis and drug therapy of hyperthyroidism]. Bürgi U; Gerber H; Peter HJ Schweiz Med Wochenschr; 1995 Aug; 125(31-32):1489-94. PubMed ID: 7545825 [TBL] [Abstract][Full Text] [Related]
8. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329 [TBL] [Abstract][Full Text] [Related]
9. Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study. Wang L; Wang B; Chen SR; Hou X; Wang XF; Zhao SH; Song JQ; Wang YG Horm Metab Res; 2016 Sep; 48(9):559-64. PubMed ID: 27392116 [TBL] [Abstract][Full Text] [Related]
10. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819 [TBL] [Abstract][Full Text] [Related]
11. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243 [TBL] [Abstract][Full Text] [Related]
12. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Laurberg P; Berman DC; Andersen S; Bülow Pedersen I Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677 [TBL] [Abstract][Full Text] [Related]
13. [Hyperthyroidism in Graves' disease--antithyroid drug treatment]. Schumm-Draeger PM Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():41-5. PubMed ID: 10355049 [TBL] [Abstract][Full Text] [Related]
14. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704 [TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations and early effectiveness of methimazole in patients with graves' hyperthyroidism-related severe hepatic dysfunction. Li C; Wang KL; Hu JH; Su HB Scand J Gastroenterol; 2023; 58(12):1514-1522. PubMed ID: 37545358 [TBL] [Abstract][Full Text] [Related]
16. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. Vos XG; Endert E; Zwinderman AH; Tijssen JG; Wiersinga WM J Clin Endocrinol Metab; 2016 Apr; 101(4):1381-9. PubMed ID: 26863422 [TBL] [Abstract][Full Text] [Related]
17. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575 [TBL] [Abstract][Full Text] [Related]